Endometrial Cancer Recognition via EEG Dependent upon 14-3-3 Protein Leading to an Ontological Diagnosis

Authors: Marios Poulos, Eirini Maliagani, Minas Paschopoulos, George Bokos

Abstract:

The purpose of my research proposal is to demonstrate that there is a relationship between EEG and endometrial cancer. The above relationship is based on an Aristotelian Syllogism; since it is known that the 14-3-3 protein is related to the electrical activity of the brain via control of the flow of Na+ and K+ ions and since it is also known that many types of cancer are associated with 14-3-3 protein, it is possible that there is a relationship between EEG and cancer. This research will be carried out by well-defined diagnostic indicators, obtained via the EEG, using signal processing procedures and pattern recognition tools such as neural networks in order to recognize the endometrial cancer type. The current research shall compare the findings from EEG and hysteroscopy performed on women of a wide age range. Moreover, this practice could be expanded to other types of cancer. The implementation of this methodology will be completed with the creation of an ontology. This ontology shall define the concepts existing in this research-s domain and the relationships between them. It will represent the types of relationships between hysteroscopy and EEG findings.

Keywords: Bioinformatics, Protein 14-3-3, EEG, Endometrial cancer, Ontology.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1071804

References:

[1] W. E. Winter, III, and J. A. Gosewehr. (2006, May 19). Uterine Cancer. eMedicine. Available: http://emedicine.medscape.com/article/258148- overview
[2] F. A. Saksouk, and Y. A. Al-Kadhi. (2007, Feb. 2). Endometrium, Carcinoma. eMedicine. Available: http://emedicine.medscape.com /article/403578-overview
[3] R. Vanni, and G. Parodo. (2004, Nov.). Uterus Tumours: an Overview. Atlas Genet Cytogenet Oncol Haematol. Available: http://AtlasGeneticsOncology.org/Tumors/UterusTumOverviewID5157. html
[4] C. Dolinsky. (2008, Feb. 29). Endometrial Cancer: The Basics. OncoLink: Abramson Cancer Center of the University of Pennsylvania. Available: http://www.oncolink.org/types/article.cfm?c=6&s=18&ss= 137&id=8227&CFID=920688&CFTOKEN=55968454
[5] M. Barati, S. Masihi, and F. Moramezi. "Hysteroscopic View of Endometrial Hyperplasia." Pak J Med Sci, vol. 24, no. 1, pp. 65-68, Jan.-Mar. 2008.
[6] J. W. Chiang, and S. B. Tate. (2008, Sep. 3). Premalignant Lesions of the Endometrium, eMedicine. Available: http://emedicine.medscape. com/article/269919-overview
[7] H. Nakayama, T. Sano, A. Motegi, T. Oyama, and T. Nakajima. "Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma." Pathol Int, vol. 55, no. 11, pp. 707-715, Nov. 2005.
[8] P. Mhawech, A. Benz, C. Cerato, V. Greloz, M. Assaly, J. C. Desmond, H. P. Koeffler, D. Lodygin, H. Hermeking, F. Herrmann, and J. Schwaller. "Downregulation of 14-3-3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation." Modern Pathology, vol. 18, pp. 340-348, 2005.
[9] A. Benzinger, N. Muster, H. B. Koch, J. R. Yates, III, and H. Hermeking. "Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer." Mol Cell Proteomics, vol. 4, no. 6, pp. 785-795, June 2005.
[10] T. Sano, H. Shimooka, P. Weixa, A. Segawa, Z. Jian, A. Motegi, H. Nakayama, T. Oyama, and T. Nakajima. "Immunohistochemical expression of 14-3-3 sigma protein in various histological subtypes of uterine cervical cancers." Pathol Int., vol. 54, no. 10, pp. 743-750, Oct. 2004.
[11] M. K. Dougherty and D. K. Morrison. "Unlocking the code of 14-3-3." Journal of Cell Science, vol. 117, pp. 1875-1884, 2004.
[12] C. B. Umbricht, E. Evron, E. Gabrielson, A. Ferguson, J. Marks, and S. Sukuma. "Hypermethylation of 14-3-3¤â (stratifin) is an early event in breast cancer." Oncogene, vol. 20, no. 26, pp. 3348-3353, 2001.
[13] T. Fan, R. Li, N. W. Todd, Q. Qiu, H.B. Fang, H. Wang, J. Shen, R. Y. Zhao, N. P. Caraway, R. L. Katz, S. A. Stassl, and F. Jiang. "Upregulation of 14-3-3 in lung cancer and its implication as prognostic and therapeutic target." Cancer Research, vol. 67, pp. 7901-7906, August 15, 2007.
[14] Emory University (2007, Dec. 29). Lung cancer cells' survival gene seen as drug target. ScienceDaily. Available: http://www.sciencedaily. com-/releases/2007/12/ 071226003936.htm
[15] M. Ishii and Y. Kurachi. "The 14-3-3 protein as a novel regulator of ion channel localization." J. Physiol., vol. 545(Pt. 1), pp. 2, Nov. 15, 2002.
[16] Z. Nazar, S. Farooq, S. M. Sultan, M. Ahmed, I. U. Rehman, and K. A. Mufti. "An audit of electroencephalography (EEG) referral in tertiary care teaching hospital." J. Pak. Psych Society, vol. 2, no. 1, pp. 24-26, Jan.-Jun. 2005.
[17] D. Quinonez. "Common applications of electrophysiology (EEG) in the past and today: the technologist-s view." Electroencephalogr. Clin. Neurophysiol., vol. 106, no. 2, pp. 108-112, Feb. 1998.
[18] K. Ito, T. Suzuki, J. Akahira, M. Sakuma, S. Saitou, S. Okamoto, H. Niikura, K. Okamura, N. Yaegashi, H. Sasano, and S. Inoue. "14-3-3 sigma in endometrial cancer: A possible prognostic marker in early-stage cancer." Clinical Cancer Research, vol. 11, pp. 7384-7391, October 15, 2005.
[19] S. Rajan, R. Preisig-M├╝ller, E. Wischmeyer, R. Nehring, P. J. Hanley, V. Renigunta, B. Musset, G. Schlichthörl, C. Derst, A. Karschin, and J. Daut. "Interaction with 14-3-3 proteins promotes functional expression of the potassium channels TASK-1 and TASK-3." Journal of Physiology, vol. 545, no. 1, pp.13-26, 2002.
[20] P. Olejniczak. "Neurophysiologic basis of EEG." J. Clin. Neurophysiol., vol. 23, pp. 186-189, 2006.
[21] M. Poulos, G. Bokos, and F. Vaioulis. "Towards the semantic extraction of digital signatures for librarian image-identification purposes." Journal of the American Society for Information Science and Technology, vol. 59, no. 5, pp. 1-11, 2008.
[22] R. A. Haag. "Supermolecular drug-delivery systems based on polymeric core-shell architecture." Chem. Int. Ed., vol. 43, pp. 278-282, 2004.
[23] Y. Guo, et al. "The diagnosis of major depression in patients with cancer: A comparative approach." Psychosomatics, vol. 47, no. 5, pp. 376-384, 2006.
[24] K. Putnam, M. McSweeney, and B. Lauren. "Depressive symptoms and baseline prefrontal EEG alpha activity: a study utilizing ecological momentary assessment." Biological Psychology, vol. 77, no. 2, Feb. 2008.
[25] L. Schwartz, M. Lander, and H. M. Chochinov. "Current management of depression in cancer patients." Oncology (Williston Park), vol. 16, no. 8, pp. 1102-1110, Aug. 2002.
[26] M. Poulos, M. Rangoussi, N. Alexandris, and A. Evangelou. "On the use of EEG features towards person identification via neural networks." Medical Informatics & the Internet in Medicine, vol. 26, pp. 35-48, 2001.
[27] M. Poulos, M.Rangousi, N. Alexandris, and A. Evangelou. "Person identification from the EEG using nonlinear signal classification." Methods of Information in Medicine, vol. 41, pp. 64-75, 2002.
[28] A. J. Swerdlow and M. E. Jones. "Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study." Journal of the National Cancer Institute, vol. 97, no. 5, pp. 375-384, 2005.
[29] W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod. "Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use." Carcinogenesis, vol. 28, no. 10, pp. 2139-2142, 2007.
[30] T. R. Gruber. "Toward principles for the design of ontologies used for knowledge sharing." International Journal Human-Computer Studies, vol. 43, pp. 907-928, 1993.
[31] M. Cannataro, A. Massara, and P. Veltri. "The OnBrowser ontology manager: Managing ontologies on the grid," in Proc. of the ECAI 2004 Workshop on Semantic Intelligent Middleware for the Web and the Grid, Valencia, Spain, 2004, vol. 111.
[32] M. A. Sicilia. "Metadata, semantics, and ontology: Providing meaning to information resources." International Journal of Metadata, Semantics and Ontologies, vol. 1, no. 1, 2006.
[33] U. Boas, and P. Heegaard. "Dendrimers in drug research." Chem. Soc. Rev., vol. 33, pp. 43-63, 2004.
[34] S. Stiriba, H. Frey, and R. A. Haag. "Dendritic polymers in biomedical applications: From potential to clinical use in diagnostics and therapy." Chem. Int. Ed., vol. 41, no. 8, pp. 1329-1334, 2002.
[35] E. Katz, and I. Willner."Biomolecule-functionalized carbon nanotubes: Applications in nanobioelectronics." Chem. Phys. Chem., vol. 5, pp. 1084-1104, 2004.